What Collaborative Trajectory Analysis Project does

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge, MA-based precompetitive research coalition founded in 2017 and operating under the public-facing brand 'cTAP.' The organization aggregates longitudinal clinical data from Duchenne muscular dystrophy (DMD) patients across a network of 47 collaborating patient organizations, academic research centers, and industry partners. As of 2025, cTAP's data platform holds 18,000+ clinic visits, 7,500+ patient-years of follow-up, and records on 2,500+ boys and young men with DMD, supporting what the company describes as 'strategic, collaborative, non-competitive patient data science.'

The core products are the cTAP Duchenne Program — a shared trajectory data infrastructure for DMD — and the May 2026 cTAP Duchenne Loss of Ambulation Prognostic Score, a five-tier validated risk classifier published in Neurology that uses rise-from-floor and 10-meter walk/run assessments to stratify patients by median time to loss of ambulation. The organization has produced 15 peer-reviewed publications, 70 abstracts and posters, and 100+ scientific meetings, channeling outputs through academic publications, conferences, and direct stakeholder partnerships rather than commercial distribution.

cTAP is structured as a nonprofit coalition rather than a commercial entity. There is no product pricing, subscription, or fee model disclosed. Funding flows implicitly through collaborative research partnerships with patient organizations, industry sponsors, and research grants for precompetitive work; no equity funding rounds, parent company, or commercial revenue lines are disclosed. Leadership is led by founder and Executive Director Susan Ward. The operating footprint claims global reach, with a stated mission to accelerate research for approximately 300,000 people worldwide affected by rare neuromuscular diseases, and the website exposes a 'What's Next' program signaling potential expansion beyond DMD.

Name

Collaborative Trajectory Analysis Project

Legal name

Collaborative Trajectory Analysis Project

Website

https://ctap-duchenne.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge-based precompetitive research coalition founded in 2017 that aggregates longitudinal Duchenne muscular dystrophy patient data across 47 partner institutions and develops validated prognostic tools to accelerate rare neuromuscular disease research.

Ownership category

akta.pro rank

Product category

Rare Disease Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Patient Registries & Chronic Disease Registry Analytics (HLACAHAH)

akta.pro secondary industries

Clinical Trial Management Systems (CTMS) (HLACAOAD), Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer) (HLAJANAG)

Keywords

• Rare disease research
• Patient data science
• Precompetitive research coalition
• Clinical trial design tools
• Neuromuscular disease research

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Precompetitive Research Funding: cTAP operates as a nonprofit coalition funded by patient organizations, industry partners, and research grants to conduct precompetitive research in rare neuromuscular diseases. Revenue appears to come from collaborative partnerships and research support rather than commercial product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

cTAP operates a precompetitive research coalition that aggregates and analyzes longitudinal patient trajectory data from rare neuromuscular disease patients (primarily Duchenne muscular dystrophy) across 47 collaborating institutions. It provides strategic, non-competitive patient data science, develops validated prognostic tools such as the Loss of Ambulation Prognostic Score, and supports clinical trial design and patient counseling through evidence-based disease progression models.

Product overview

cTAP is a precompetitive research coalition that operates as a unified platform for patient data science in rare neuromuscular diseases. The core offering consists of the cTAP Duchenne Program, which provides a shared data infrastructure aggregating clinical trajectory data from thousands of patients across multiple institutions, complemented by specific prognostic tools like the Duchenne Loss of Ambulation Prognostic Score. These offerings work together to accelerate clinical research by enabling cross-stakeholder collaboration, strategic data support, and evidence-based prediction models for clinical trial design and patient counseling.

Differentiator

Problem solved

Functional benefit

Products and services

• cTAP Duchenne Program A collaborative research program focused on analyzing patient trajectory data for Duchenne muscular dystrophy. It aggregates clinical data from over 18,000 clinic visits, 7,500+ patient years of follow-up, and 2,500+ boys and young men with DMD across 47 collaborating institutions to accelerate research for rare neuromuscular communities.
• Duchenne Loss of Ambulation Prognostic Score A validated prognostic tool that uses two functional assessments (rise from floor and 10-meter walk/run) to classify DMD patients into five risk groups, with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk). Developed from data on over 600 boys with DMD and validated on an independent dataset, it supports clinical decision-making, patient counseling, and clinical trial design.

Quantifiable outcome

• Prognostic score classifies DMD patients into five risk groups with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• 47 Collaborating Institutions and OrganizationscoreStrategic or Co-development PartnercTAP maintains a coalition of 47 collaborating institutions and organizations contributing to and benefiting from the shared patient data platform. These include patient organizations, scientific leaders, researchers, and industry partners working collaboratively on precompetitive research in rare neuromuscular diseases.

Scale indicators8 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Critical Path Institute (C-Path): C-Path is the largest US precompetitive research consortium, convening industry, regulators, academics, and patient groups to share data and build tools that accelerate therapeutic development across multiple disease areas. Like cTAP, it operates a coalition model focused on shared data science and regulatory-grade evidence.
• Treat-NMD: Treat-NMD is an international neuromuscular disease network that aggregates patient data, runs registries (including for DMD), and supports clinical trial readiness. It overlaps cTAP directly in DMD natural-history data and neuromuscular trial enablement.
• Parent Project Muscular Dystrophy (PPMD): PPMD operates the Duchenne Registry, one of the most established patient-reported and clinical DMD data repositories in the US. It is directly comparable to cTAP as a DMD patient-data and advocacy-led research organization.
• Wellstone Muscular Dystrophy Research Centers: The NIH-funded Wellstone Centers focus on muscular dystrophy research, including DMD, and share patient-level data and resources across institutions. They are partial peers given their overlapping scientific scope but academic/government ownership model.

Regional players

• Cincinnati Children's Hospital Medical Center - DMD Research Programs: Cincinnati Children's is a leading DMD research site with substantial longitudinal patient data and clinical-trial expertise. It is a major potential contributor/competitor to cTAP's data consortium model.

Broad incumbents

• Cystic Fibrosis Foundation Patient Registry: The CFF Patient Registry is the prototypical rare-disease longitudinal clinical registry used to inform trial design, drug approval, and outcomes research. It is a well-established comparator model for how a single-indication disease registry creates durable research infrastructure.

Emerging players

• CoRDS (Sanford Research Coordination of Rare Diseases): CoRDS is a global rare-disease patient registry that collects de-identified data across multiple rare conditions, including neuromuscular diseases. It is comparable to cTAP's cross-institutional rare-disease data platform approach.

Others

• FD/MAS Alliance & Related Registries: FD/MAS Alliance operates a patient registry and supports rare bone disease research through collaborative models, illustrating how rare-disease patient organizations are increasingly building structured longitudinal data assets, similar to cTAP's neuromuscular focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ctap-duchenne

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Collaborative Trajectory Analysis Project